Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

NASDAQ:IKNA

Ikena Oncology, Inc.

Last Close

1.68

26/07 20:00

Market Cap

78.18M

Beta: 0.75

Volume Today

114.30K

Avg: 63.66K

PE Ratio

−0.98

PFCF: −0.87

Filings Not Available